GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Shiller PE Ratio

ACORQ (Acorda Therapeutics) Shiller PE Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Acorda Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Acorda Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Shiller PE Ratio Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acorda Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acorda Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Shiller PE Ratio falls into.



Acorda Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Acorda Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Acorda Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-22.06/131.7762*131.7762
=-22.060

Current CPI (Mar. 2024) = 131.7762.

Acorda Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 13.200 100.560 17.298
201409 33.600 100.428 44.088
201412 1.200 99.070 1.596
201503 -8.400 99.621 -11.111
201506 2.400 100.684 3.141
201509 10.800 100.392 14.176
201512 25.200 99.792 33.277
201603 -1.200 100.470 -1.574
201606 -48.000 101.688 -62.203
201609 -33.600 101.861 -43.468
201612 -8.400 101.863 -10.867
201703 -49.200 102.862 -63.030
201706 -21.600 103.349 -27.541
201709 -66.000 104.136 -83.518
201712 -443.999 104.011 -562.522
201803 -21.600 105.290 -27.034
201806 117.600 106.317 145.761
201809 -34.800 106.507 -43.057
201812 24.000 105.998 29.837
201903 -120.000 107.251 -147.441
201906 -69.600 108.070 -84.868
201909 -665.999 108.329 -810.148
201912 165.600 108.420 201.274
202003 -16.200 108.902 -19.603
202006 -43.800 108.767 -53.066
202009 6.400 109.815 7.680
202012 -196.400 109.897 -235.501
202103 -70.600 111.754 -83.249
202106 -45.800 114.631 -52.650
202109 -48.600 115.734 -55.336
202112 -34.600 117.630 -38.761
202203 -37.000 121.301 -40.195
202206 -54.010 125.017 -56.930
202209 -11.170 125.227 -11.754
202212 11.400 125.222 11.997
202303 -13.540 127.348 -14.011
202306 -7.550 128.729 -7.729
202309 -7.160 129.860 -7.266
202312 -175.320 129.419 -178.513
202403 -22.060 131.776 -22.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acorda Therapeutics  (OTCPK:ACORQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Acorda Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123

Acorda Therapeutics Headlines

From GuruFocus

Q4 2020 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc CEO Video Presentation Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc Q&A Call Transcript

By GuruFocus Research 02-06-2024

Q2 2019 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q4 2021 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q2 2022 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q4 2022 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q3 2020 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024